Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018)

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926 · see citing works

Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298 · see citing works

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · see citing works

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997–2016

Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825 · see citing works

Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials

Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793 · see citing works

Changes in the epidemiological landscape of invasive candidiasis

Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547 · see citing works

Fluconazole resistance in <em>Candida</em> species: a current perspective

Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542 · see citing works

Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012

Pfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484 · see citing works

Manual of Clinical Microbiology

Carroll, K. C., & Pfaller, M. A. (2020) · ASM Press eBooks · doi:10.1128/9781683670438.mcm · Cited by 409 · see citing works

Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance

Pfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N., & Castanheira, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00308-13 · Cited by 237 · see citing works

Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults

Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161 · see citing works

Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin

Ong, V. S., Hough, G., Schlosser, M., Bartizal, K. F., Balkovec, J. M., James, K. D., & Krishnan, B. R. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00701-16 · Cited by 126 · see citing works

Echinocandin Resistance in <i>Candida</i> Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches

Beyda, N. D., Lewis, R. E., & Garey, K. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r020 · Cited by 109 · see citing works

Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?

Oxman, D., Chow, J. K. L., Frendl, G., Hadley, S., Hershkovitz, S., Ireland, P., McDermott, L. A., Tsai, K., Marty, F. M., Kontoyiannis, D. P., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq136 · Cited by 104 · see citing works

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, againstCandidaandAspergillusspp., including echinocandin- and azole-resistant isolates

Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Jones, R. N., & Castanheira, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw214 · Cited by 103 · see citing works

What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead

Bassetti, M., Righi, E., Montravers, P., & Cornely, O. A. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx445 · Cited by 101 · see citing works

Candida guilliermondii and Other Species of Candida Misidentified as Candida famata: Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs

Castanheira, M., Woosley, L. N., Diekema, D. J., Jones, R. N., & Pfaller, M. A. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01686-12 · Cited by 100 · see citing works

Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy

Sofjan, A. K., Mitchell, A. C., Shah, D. N., Nguyen, T. H., Sim, M., Trojcak, A., Beyda, N. D., & Garey, K. W. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.02.013 · Cited by 99 · see citing works

CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility

Krishnan, B. R., James, K. D., Polowy, K., Bryant, B. J., Vaidya, A., Smith, S., & Laudeman, C. P. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.89 · Cited by 98 · see citing works

Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme

Pfaller, M. A., Woosley, L. N., Messer, S. A., Jones, R. N., & Castanheira, M. (2012) · Mycopathologia · doi:10.1007/s11046-012-9551-x · Cited by 84 · see citing works

CD101: a novel long-acting echinocandin

Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81 · see citing works

Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties

James, K. D., Laudeman, C. P., Malkar, N. B., Krishnan, R., & Polowy, K. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01541-16 · Cited by 73 · see citing works

Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections

Castanheira, M., Messer, S. A., Jones, R. N., Farrell, D. J., & Pfaller, M. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.06.007 · Cited by 66 · see citing works

Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species

Locke, J. B., Almaguer, A. L., Zuill, D. E., & Bartizal, K. F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00620-16 · Cited by 66 · see citing works

CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program

Pfaller, M. A., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.03.028 · Cited by 65 · see citing works

Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design

Lepak, A. J., Zhao, M., VanScoy, B. D., Ambrose, P. G., & Andes, D. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02154-17 · Cited by 63 · see citing works

In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories

Pfaller, M. A., Rhomberg, P. R., Wiederhold, N. P., Gibas, C. F. C., Sanders, C. J., Fan, H., Mele, J., Kovanda, L. L., & Castanheira, M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01230-18 · Cited by 62 · see citing works

Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program

Pfaller, M. A., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02045-16 · Cited by 53 · see citing works

Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method

Arendrup, M. C., Meletiadis, J., Zaragoza, Ó., Jørgensen, K. M., Marcos-Zambrano, L. J., Kanioura, L., Cuenca‐Estrella, M., Mouton, J. W., & Guinea, J. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.021 · Cited by 45 · see citing works

Trends in antifungal use in US hospitals, 2006–12

Vallabhaneni, S., Baggs, J., Tsay, S., Srinivasan, A. R., Jernigan, J. A., & Jackson, B. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky270 · Cited by 45 · see citing works

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

Bader, J. C., Lakota, E. A., Flanagan, S., Ong, V. S., Sandison, T., Rubino, C. M., Bhavnani, S. M., & Ambrose, P. G. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02614-17 · Cited by 44 · see citing works

CD101, a novel echinocandin, possesses potent antibiofilm activity against early and mature Candida albicans biofilms

Chandra, J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-17 · Cited by 36 · see citing works

Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study

Yamaguchi, M., Kurokawa, T., Ishiyama, K., Aoki, G., Ueda, M., Matano, S., Takami, A., Yamazaki, H., Sawazaki, A., Yamauchi, H., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1277-1 · Cited by 31 · see citing works

Antifungal use in hospitalized adults in U.S. academic health centers

Pakyz, A. L., Gurgle, H. E., & Oinonen, M. J. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100423 · Cited by 22 · see citing works

In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp.

Hall, D., Bonifas, R., Stapert, L., Thwaites, M., Shinabarger, D. L., & Pillar, C. M. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.07.007 · Cited by 22 · see citing works

Safety of high-dose micafungin for patients with hematological diseases

Yamazaki, S., Nakamura, F., Yoshimi, A., Ichikawa, M., Nannya, Y., & Kurokawa, M. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.885514 · Cited by 19 · see citing works

EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates

Arendrup, M. C., Jørgensen, K. M., Hare, R. K., Cuenca‐Estrella, M., & Zaragoza, Ó. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00659-19 · Cited by 17 · see citing works

Variability in antifungal utilization among neonatal, pediatric, and adult inpatients in academic medical centers throughout the United States of America

Stultz, J. S., Kohinke, R. M., & Pakyz, A. L. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3410-4 · Cited by 15 · see citing works

Consumption of systemic antifungal agents among acute care hospitals in Catalonia (Spain), 2008–2013

Fondevilla, E., Grau, S., Mojal, S., Palomar, M., Matas, L., & Gudiol, F. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2016.1096776 · Cited by 14 · see citing works

Systemic antifungal drug use in Belgium—One of the biggest antifungal consumers in Europe

Goemaere, B., Lagrou, K., Spriet, I., Hendrickx, M., Vandael, E., Becker, P., & Catry, B. (2019) · Mycoses · doi:10.1111/myc.12912 · Cited by 14 · see citing works

Invasive Fungal Infections and Approaches to Their Diagnosis

Pfaller, M. A. (2015) · Methods in microbiology · doi:10.1016/bs.mim.2015.05.002 · Cited by 10 · see citing works

Echinocandin Use in Hospitalized Patients: A Multi-institutional Study

Garey, K. W., Aitken, S. L., Dima-Ala, A., Beyda, N. D., Kuper, K. M., Xie, Y., & Koo, H. L. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000412 · Cited by 8 · see citing works

2115. Activity of a Long-Acting Echinocandin Rezafungin and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018

Pfaller, M. A., Carvalhaes, C. G., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz360.1795 · Cited by 1 · see citing works

Diagnosis and Treatment of Invasive Candidiasis

Barantsevich, N. E., & Петровна, Б. Е. (2022) · Antibiotics · doi:10.3390/antibiotics11060718 · Cited by 193 · see citing works

<i>Candida auris</i> Genetics and Emergence

Chowdhary, A., Jain, K., & Chauhan, N. (2023) · Annual Review of Microbiology · doi:10.1146/annurev-micro-032521-015858 · Cited by 158 · see citing works

Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease

Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 160 · see citing works

Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins

García‐Effrón, G. (2020) · Journal of Fungi · doi:10.3390/jof6040262 · Cited by 134 · see citing works

Review on Current Status of Echinocandins Use

Mroczyńska, M., & Brillowska‐Dąbrowska, A. (2020) · Antibiotics · doi:10.3390/antibiotics9050227 · Cited by 108 · see citing works

Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches

Tortorano, A. M., Prigitano, A., Morroni, G., Brescini, L., & Barchiesi, F. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s274872 · Cited by 96 · see citing works

Fungal Quorum-Sensing Molecules: A Review of Their Antifungal Effect against Candida Biofilms

Kovács, R., & Majoros, L. (2020) · Journal of Fungi · doi:10.3390/jof6030099 · Cited by 96 · see citing works

Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective

Lamoth, F., Lewis, R. E., & Kontoyiannis, D. P. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1070 · Cited by 79 · see citing works

Novel antifungal agents in clinical trials

Jacobs, S. E., Zagaliotis, P., & Walsh, T. J. (2021) · F1000Research · doi:10.12688/f1000research.28327.1 · Cited by 75 · see citing works

Candida parapsilosis complex in the clinical setting

Govrins, M. A., & Lass‐Flörl, C. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00961-8 · Cited by 77 · see citing works

Rezafungin: a novel antifungal for the treatment of invasive candidiasis

Ham, Y. Y., Lewis, J. S., & Thompson, G. R. (2021) · Future Microbiology · doi:10.2217/fmb-2020-0217 · Cited by 66 · see citing works

Rezafungin: First Approval

Syed, Y. Y. (2023) · Drugs · doi:10.1007/s40265-023-01891-8 · Cited by 66 · see citing works

Aspergillosis: an Update on Clinical Spectrum, Diagnostic Schemes, and Management

Kanaujia, R., Singh, S., & Rudramurthy, S. M. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00461-5 · Cited by 63 · see citing works

Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species

Fakhim, H., Badali, H., Dannaoui, É., Nasirian, M., Jahangiri, F., Raei, M., Vaseghi, N., Ahmadikia, K., & Vaezi, A. (2022) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2022.101310 · Cited by 57 · see citing works

Amphotericin B in the Era of New Antifungals: Where Will It Stand?

Akinosoglou, K., Rigopoulos, E. A., Papageorgiou, D., Schinas, G., Polyzou, E., Dimopoulou, E., Gogos, C. A., & Dimοpoulos, G. (2024) · Journal of Fungi · doi:10.3390/jof10040278 · Cited by 56 · see citing works

Antifungal Pipeline

McCarty, T. P., & Pappas, P. G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.732223 · Cited by 47 · see citing works

Recent drug development and treatments for fungal infections

Roy, M., Karhana, S., Shamsuzzaman, M., & Khan, M. A. (2023) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-00999-z · Cited by 45 · see citing works

Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects

Lu, X., Zhou, J., Ming, Y., Wang, Y., He, R., Li, Y., Feng, L., Zeng, B., Du, Y., & Wang, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.013 · Cited by 48 · see citing works

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

Kovács, R., Tóth, Z., Locke, J. B., Forgács, L., Kardos, G., Nagy, F., Borman, A. M., & Majoros, L. (2021) · Microorganisms · doi:10.3390/microorganisms9040863 · Cited by 43 · see citing works

Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020)

Carvalhaes, C. G., Klauer, A. L., Rhomberg, P. R., Pfaller, M. A., & Castanheira, M. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.02449-21 · Cited by 40 · see citing works

Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin

Oliva, A., Rosa, F. G. D., Mikulska, M., Pea, F., Sanguinetti, M., Tascini, C., & Venditti, M. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2240956 · Cited by 40 · see citing works

The antifungal pipeline for invasive fungal diseases: what does the future hold?

Neoh, C. F., Jeong, W., Kong, D. C. M., & Slavin, M. A. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2203383 · Cited by 37 · see citing works

The Role of Novel Antifungals in the Management of Candidiasis: A Clinical Perspective

Ordaya, E. E., Clement, J., & Vergidis, P. I. (2023) · Mycopathologia · doi:10.1007/s11046-023-00759-5 · Cited by 37 · see citing works

Critical appraisal beyond clinical guidelines for intraabdominal candidiasis

Maseda, E., Martín‐Loeches, I., Zaragoza, R., Pemán, J., Fortün, J., Grau, S., Aguilar, G., Varela, M., Borges-Sa, M., Giménez, M.-J., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04673-6 · Cited by 35 · see citing works

How urgent is the need for new antifungals?

Stewart, A. G., & Paterson, D. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1935868 · Cited by 36 · see citing works

Investigational Agents for the Treatment of Resistant Yeasts and Molds

Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32 · see citing works

The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives

de Souza, C. M., Bezerra, B. T., Mellon, D. A., & de Oliveira, H. C. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100341 · Cited by 35 · see citing works

Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management

Akinosoglou, K., Livieratos, A., Asimos, K., Donders, F., & Donders, G. G. G. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121555 · Cited by 30 · see citing works

Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis

Roepcke, S., Passarell, J. A., Walker, H., & Flanagan, S. D. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00916-23 · Cited by 25 · see citing works

The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models

Cushion, M. T., & Ashbaugh, A. (2021) · Journal of Fungi · doi:10.3390/jof7090747 · Cited by 25 · see citing works

Antifungal Activity of Mexican Propolis on Clinical Isolates of Candida Species

Rivera-Yañez, C. R., Ruiz-Hurtado, P. A., Reyes‐Reali, J., Mendoza‐Ramos, M. I., Vargas-Dı́az, M. E., Hernández-Sánchez, K. M., Pozo‐Molina, G., Méndez-Catalá, C. F., García-Romo, G. S., Pedroza‐González, A., et al. (2022) · Molecules · doi:10.3390/molecules27175651 · Cited by 24 · see citing works

Candida glabrata: A Tale of Stealth and Endurance

Askari, F., & Kaur, R. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00477 · Cited by 21 · see citing works

Echinocandins Localized to the Target-Harboring Cell Surface Are Not Degraded but Those Entering the Vacuole Are

Jaber, Q. Z., Logviniuk, D., Yona, A., & Fridman, M. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00060 · Cited by 22 · see citing works

Biocontrol of Candida albicans by Antagonistic Microorganisms and Bioactive Compounds

Li, H., Yang, J., Zhang, X., Xu, X., Song, F., & Li, H. (2022) · Antibiotics · doi:10.3390/antibiotics11091238 · Cited by 22 · see citing works

Antifungal resistance, combinations and pipeline: oh my!

Stover, K. R., Hawkins, B. K., Keck, J. M., Barber, K. E., & Cretella, D. A. (2023) · Drugs in Context · doi:10.7573/dic.2023-7-1 · Cited by 19 · see citing works

Beyond ergosterol: Strategies for combatting antifungal resistance in Aspergillus fumigatus and Candida auris

Cruz, R., & Wuest, W. M. (2023) · Tetrahedron · doi:10.1016/j.tet.2023.133268 · Cited by 19 · see citing works

An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections

Mueller, S. W., Kedzior, S. K., Miller, M. A., Reynolds, P., Kiser, T. H., Kršák, M., & Molina, K. C. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1892075 · Cited by 19 · see citing works

Activity of rezafungin against Candida auris

Locke, J. B., Andes, D. R., Flanagan, S., Redell, M. A., Ong, V. S., Aram, J. A., Pappas, P. G., Castanheira, M., & Thompson, G. R. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf124 · Cited by 17 · see citing works

Pipeline of Novel Antifungals for Invasive Fungal Disease in Transplant Recipients: A Pediatric Perspective

Hsu, A. J., Hanisch, B. R., Fisher, B. T., & Huppler, A. R. (2024) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piad115 · Cited by 15 · see citing works

Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: A case report

Adeel, A., Qu, M. D., Siddiqui, E. U., Levitz, S. M., & Ellison, R. T. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab431 · Cited by 14 · see citing works

Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program

Viceconte, G., Buonomo, A. R., Esposito, N. D. P., Cattaneo, L., Somma, T., Scirocco, M. M., Mainolfi, C. G., & Gentile, I. (2024) · Microorganisms · doi:10.3390/microorganisms12050903 · Cited by 13 · see citing works

Phospholipid/protein co-mediated assembly of Cu2O nanoparticles for specific inhibition of growth and biofilm formation of pathogenic fungi

Peng, L., Wei, H. R., Tian, L., Xu, J., Li, M., & Yu, Q. (2020) · Science China Materials · doi:10.1007/s40843-020-1457-1 · Cited by 12 · see citing works

Microbial spectrum and susceptibility profile of opportunistic pathogens isolated from cancer patients attending a tertiary healthcare centre in Akure, Nigeria

Oluyele, O., Oladunmoye, M. K., Ogundare, A. O., Onifade, A. K., & Okunnuga, N. A. (2023) · Microbes Infection and Chemotherapy · doi:10.54034/mic.e1961 · Cited by 11 · see citing works

An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis

Sharma, D., & Vázquez, J. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2331775 · Cited by 11 · see citing works

New Perspectives on Antimicrobial Agents: Rezafungin

Forrister, N. M., McCarty, T. P., & Pappas, P. G. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00646-23 · Cited by 10 · see citing works

An update on newer antifungals

Akinosoglou, K., Papageorgiou, D., Gogos, C. A., & Dimοpoulos, G. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2025.2461566 · Cited by 10 · see citing works

Antifungal chemotherapies and immunotherapies for the future

Armstrong-James, D. P. H. (2022) · Parasite Immunology · doi:10.1111/pim.12960 · Cited by 9 · see citing works

Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation

Bassetti, M., Stewart, A. G., Bartalucci, C., Vena, A., Giacobbe, D. R., & Roberts, J. A. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2424899 · Cited by 9 · see citing works

Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix

August, B., & Kale-Pradhan, P. B. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2926 · Cited by 8 · see citing works

Antifungal echinocandins: Historical discovery, comprehensive structure-activity relationships, resistance mechanisms and future developments

Lang, M., Susan, V., Brendel, L., Sabou, M., & Bourel‐Bonnet, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118102 · Cited by 7 · see citing works

Evaluation of the Post‐Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata

Carvalhaes, C. G., Rhomberg, P. R., Pfaller, M. A., Locke, J. B., & Castanheira, M. (2022) · Mycoses · doi:10.1111/myc.13490 · Cited by 6 · see citing works

New and emerging drugs for the treatment of invasive fungal infections

Maves, R. C., & Fowler, M. N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2568547 · Cited by 5 · see citing works

Qi-Huang decoction alleviates DSS-induced colitis with Candida albicans dysbiosis by enhancing innate immune response through Dectin-1-associated signaling

Liu, C., Liu, Y., Wang, Z., Zhu, H., Luo, Q., Wu, D., Wang, T., Hu, M. S., Wang, C., & Shao, J. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156613 · Cited by 5 · see citing works

Anidulafungin is a useful surrogate marker for predicting in vitro susceptibility to rezafungin among five Candida species using CLSI methods and interpretive criteria

Winkler, M., Deshpande, L. M., Kimbrough, J. H., Karr, M. H., Rhomberg, P. R., Klauer, A. L., & Castanheira, M. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.01129-24 · Cited by 4 · see citing works

Antifungal Drug Resistance

Rhodes, J. L. (2025) · Current topics in microbiology and immunology · doi:10.1007/82_2025_327 · Cited by 3 · see citing works

Antifungal Drug Susceptibility Profile of Candida kefyr Isolated from Clinical Samples and Dairy Products

Zareshahrabadi, Z., Khaliji, S., Roudbary, M., & Zomorodian, K. (2024) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2024/6594366 · Cited by 3 · see citing works

Novel domain-structure-containing chitinases A and B of Bacillus velezensis produced by recombinant Escherichia coli cells: Synergism on chitin degradation and their potential in suppressing Candida albicans cell germination

Tran, D. M., Huynh, T. U., & Do, T. O. (2024) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2024.100402 · Cited by 3 · see citing works

New Antifungal Drugs: Discovery and Therapeutic Potential

Vicente, F., Reyes, F., & Genilloud, O. (2024) · Springer eBooks · doi:10.1007/978-981-99-5696-8_12 · Cited by 3 · see citing works

Wild-type MIC distributions and epidemiological cut-off values for ibrexafungerp, manogepix, and rezafungin against WHO fungal priority pathogens

Morelo, M. J., Firacative, C., García‐Effrón, G., Gómez, B. L., & Ceballos-Garzón, A. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107870 · Cited by 1 · see citing works

Optimization of Dosage Regimen of Rezafungin against Candida spp. Based on Pharmacokinetic/Pharmacodynamic Analysis

Hu, J., & Hu, J. (2020) · Pharmacology &amp Pharmacy · doi:10.4236/pp.2020.116008

Aspergillus-Human Interactions: From the Environment to Clinical Significance

Thammahong, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98509

Current Antifungal Drugs

Kaushik, M., Sharma, A., Gupta, S., & Gulati, P. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815080056123020008

A Brief Insight into Peptide and Non-Peptide Drugs of Fungal Origin

Mishra, A., Usha, P., & Sabareesh, V. (2024) · Springer eBooks · doi:10.1007/978-981-99-5696-8_22

Predictors for the Development of Invasive Infection of Fluconazole Non-Susceptible or Echinocandin Non-Susceptible Candida Species Across the Veterans Health Administration

Evans, C., Williams, R. J., Thind, S. K., & Gentry, C. A. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261424286

Clinical Case Report on the Use of Rezafungin in Pneumocystis jirovecii Pneumonia in a Critically Ill Patient

Fernández-Fernández, R., García-Martínez, R., Sánchez-Yebra, W., Chueca, N., & Colmenero, M. (2026) · Microorganisms · doi:10.3390/microorganisms14030683

Past, present, and emerging antifungals against Fusarium and other rare non- Aspergillus hyalohyphomycetes: a narrative review

Al‐Obaidi, M. M., Nematollahi, S., Hayes, J. F., & Nix, D. E. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2651278

Antifungal activity of rezafungin in invasive candidiasis: From bench to bed

Quindós, G., García‐Vidal, C., Martin-Martitegui, X., & Zaragoza, R. (2026) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2026.02.001

In vitro activity of rezafungin against bloodstream and intra-abdominal Candida isolates: a large EUCAST-based study

Escribano, P., Moraga, J., Burillo, A., Reigadas, E., Muñoz, P., & Guinea, J. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.09.025

2400. Activity of a Long-Acting Echinocandin, Rezafungin, Tested Against Invasive Fungal Isolates Collected Worldwide

Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Schaefer, B. A., & Castanheira, M. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy210.2053 · Cited by 2 · see citing works

1076. Activity of Rezafungin and Comparator Antifungal Agents Tested Against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019-2020)

Carvalhaes, C. G., Klauer, A. L., Rhomberg, P. R., Pfaller, M. A., Castanheira, M., & Castanheira, M. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab466.1270 · Cited by 2 · see citing works

2115. Activity of a Long-Acting Echinocandin Rezafungin and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018

Pfaller, M. A., Carvalhaes, C. G., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz360.1795 · Cited by 1 · see citing works

1731. Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021

Carvalhaes, C. G., Rhomberg, P. R., Rhomberg, P. R., Strand, G. J., Klauer, A. L., & Castanheira, M. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac492.1361 · Cited by 3 · see citing works

In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin against Invasive Fungal Isolates (2017 to 2022) in China

Yang, S., Wan, F., Zhang, M., Lin, H., Hu, L., Zhou, Z., Wang, D., Zhou, A., Ni, L., Guo, J., et al. (2024) · Journal of Fungi · doi:10.3390/jof10060397 · Cited by 6 · see citing works